A detailed history of State Street Corp transactions in Rallybio Corp stock. As of the latest transaction made, State Street Corp holds 65,222 shares of RLYB stock, worth $72,396. This represents 0.0% of its overall portfolio holdings.

Number of Shares
65,222
Previous 513,718 87.3%
Holding current value
$72,396
Previous $950,000 90.84%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.34 - $2.98 $600,984 - $1.34 Million
-448,496 Reduced 87.3%
65,222 $87,000
Q1 2024

May 15, 2024

BUY
$1.25 - $2.4 $6,435 - $12,355
5,148 Added 1.01%
513,718 $950,000
Q4 2023

Feb 14, 2024

BUY
$1.91 - $4.39 $7,151 - $16,436
3,744 Added 0.74%
508,570 $1.22 Million
Q3 2023

Nov 14, 2023

BUY
$3.37 - $6.16 $39,584 - $72,355
11,746 Added 2.38%
504,826 $1.7 Million
Q2 2023

Aug 14, 2023

BUY
$4.31 - $8.89 $944,269 - $1.95 Million
219,088 Added 79.96%
493,080 $2.79 Million
Q1 2023

May 15, 2023

BUY
$4.37 - $8.75 $18,257 - $36,557
4,178 Added 1.55%
273,992 $1.56 Million
Q4 2022

Feb 14, 2023

BUY
$4.67 - $14.86 $80,426 - $255,918
17,222 Added 6.82%
269,814 $1.77 Million
Q3 2022

Nov 15, 2022

BUY
$7.54 - $14.56 $27,460 - $53,027
3,642 Added 1.46%
252,592 $3.66 Million
Q2 2022

Aug 15, 2022

BUY
$6.26 - $13.65 $565,760 - $1.23 Million
90,377 Added 56.99%
248,950 $1.88 Million
Q1 2022

May 16, 2022

BUY
$6.91 - $15.04 $585,608 - $1.27 Million
84,748 Added 114.8%
158,573 $1.11 Million
Q4 2021

Feb 14, 2022

BUY
$9.3 - $19.91 $225,450 - $482,658
24,242 Added 48.89%
73,825 $704,000
Q3 2021

Nov 15, 2021

BUY
$10.83 - $23.4 $536,983 - $1.16 Million
49,583 New
49,583 $872,000

Others Institutions Holding RLYB

About Rallybio Corp


  • Ticker RLYB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,132,000
  • Market Cap $35.7M
  • Description
  • Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...
More about RLYB
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.